Comparative trials of Olopatadine and Fexofenadine on histamine iontophoresis induced urticaria

Comparative trials of Olopatadine and Fexofenadine on histamine iontophoresis induced urticaria - Comparative trials of Olopatadine and Fexofenadine on histamine iontophoresis induced urticaria (OF trial)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007182

Enrollment

Registered

2012-02-17

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urticaria

Interventions

Placebo Olopatadine 5mg Fexofenadine 60mg Fexofenadine 120mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Participants should consent to this trial with written agreement form. 2. Male and female 3. From 20 years old to 44 years old 4. From 50 kg to 85 kg in body weight 5. From 18.5 to 25.0 in body mass index 6. Nonsmoker

Exclusion criteria

Exclusion criteria: 1. Participate in other trial within 120 days. 2. Taking some medicine 3. History of drug allergy 4. History of sever skin disease 5. History of liver disease 6. History of heart disease 7. History of respiratory disease 8. History of digestive disease 9. History of kidney or cerebrovascular disease 10. History of malignancy 11. Low responder to histamine iontophoresis 12. Heavy drinker 13. Participant who judged as inadequate for this trial

Design outcomes

Primary

Measure	Time frame
Wheal area	—

Secondary

Measure	Time frame
Flare area, VAS for itching	—

Countries

Japan

Contacts

Public ContactJun-ichi FURUTA

University of Tsukuba Department of Dermatology, Faculty of Medicine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026